{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"126"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"description":"The count of participants with CR per IRF following the completion of study treatment (at end of treatment or at the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.","groups":[{"description":"brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles","id":"OG000","title":"A+CHP"},{"description":"cyclophosphamide, doxorubicin, vincristine, and prednisone doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles","id":"OG001","title":"CHOP"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The ITT Analysis Set includes all randomized patients. Patients are included in the treatment group assigned at randomization regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 8.34 months","title":"Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)","type":"SECONDARY","unitOfMeasure":"Participants"}